书签 分享 收藏 举报 版权申诉 / 40
上传文档赚钱

类型开发报批美国FDA的仿制药与相关问题探讨课件.ppt

  • 上传人(卖家):晟晟文业
  • 文档编号:5043566
  • 上传时间:2023-02-05
  • 格式:PPT
  • 页数:40
  • 大小:2.51MB
  • 【下载声明】
    1. 本站全部试题类文档,若标题没写含答案,则无答案;标题注明含答案的文档,主观题也可能无答案。请谨慎下单,一旦售出,不予退换。
    2. 本站全部PPT文档均不含视频和音频,PPT中出现的音频或视频标识(或文字)仅表示流程,实际无音频或视频文件。请谨慎下单,一旦售出,不予退换。
    3. 本页资料《开发报批美国FDA的仿制药与相关问题探讨课件.ppt》由用户(晟晟文业)主动上传,其收益全归该用户。163文库仅提供信息存储空间,仅对该用户上传内容的表现方式做保护处理,对上传内容本身不做任何修改或编辑。 若此文所含内容侵犯了您的版权或隐私,请立即通知163文库(点击联系客服),我们立即给予删除!
    4. 请根据预览情况,自愿下载本文。本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
    5. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007及以上版本和PDF阅读器,压缩文件请下载最新的WinRAR软件解压。
    配套讲稿:

    如PPT文件的首页显示word图标,表示该PPT已包含配套word讲稿。双击word图标可打开word文档。

    特殊限制:

    部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。

    关 键  词:
    开发 报批 美国 FDA 制药 相关 问题 探讨 课件
    资源描述:

    1、开发报批美国开发报批美国FDA的仿制药的仿制药与相关问题探讨与相关问题探讨药物制剂药物制剂目标主流市场目标主流市场仿制药研发团队CONCEPT-1 BUILD UP A TEAMINFORMATIONFORMULATIONPRODUCTREGULATORYANALYTICALBIO-PHARMACEUTICALPROJECTLEGELProduct Development Roadmap仿制药的仿制药的研发过程研发过程 Quality Acceptably low risk of failing to achieve the desired clinical attributes Pharma

    2、ceutical Quality=f drug substance,excipients,manufacturing.QbD Product and process performance characteristicsscientifically designed to meet specific objectives,not merely empirically derived from performance of test batchesWhat is QbD(?QbDQbD在制剂开发中怎么体现?在制剂开发中怎么体现?What is QbD?QbDQbD在制剂开发中怎么体现?在制剂开发

    3、中怎么体现?Essential elements of QbD Definition of the quality target product profileHigh level quality aspects of the product:purity,drug release(dissolution/disintegration time),pharmacokinetic profile,etc.Critical quality attributes(CQAs)for drug product Characteristics of DP which have impact on desi

    4、red profile Conscious attempt to study and control Critical Process Parameters(CPPs)Identification of material properties and process parameters which haveeffect on product CQAs Design Space:The multidimensional combination and interaction ofinput variables and process parameters that have been demo

    5、nstrated to provide assurance of quality Identification of a control strategy for critical process parametersWhat is QbD?QbDQbD在制剂开发中怎么体现?在制剂开发中怎么体现?Raw MaterialsEquipmentEnvironmentOperatorsVariable Inputs x“Locked”Process=Variable QualityHow Did We Work in the PastWhat is QbD?QbDQbD在制剂开发中怎么体现?在制剂开

    6、发中怎么体现?Raw MaterialsEquipmentEnvironmentOperatorsUnderstood Variable InputsxUnderstood and Controlled Process=Predefined QualityFlexible Process Design SpaceHow Can We Work in the FutureWhat is QbD?QbDQbD在制剂开发中怎么体现?在制剂开发中怎么体现?What is QbD?QbDQbD在制剂开发中怎么体现?在制剂开发中怎么体现?Raw MaterialsWet GranulationFluid

    7、Bed DryingBlendingCompressionProductDrug SubstanceExcipientsSourceAssayImpurities LODPS What is QbD?QbDQbD在制剂开发中怎么体现?在制剂开发中怎么体现?Raw MaterialsWet GranulationFluid Bed DryingBlendingCompressionWaterBinderTempSpray RateSpeedTimeP.SWhat is QbD?QbDQbD在制剂开发中怎么体现?在制剂开发中怎么体现?Raw MaterialsWet GranulationFlui

    8、d Bed DryingBlendingCompressionWhat is QbD?QbDQbD在制剂开发中怎么体现?在制剂开发中怎么体现?Raw MaterialsWet GranulationFluid Bed DryingBlendingCompressionAir FlowTempRHShock CycleP.S.What is QbD?QbDQbD在制剂开发中怎么体现?在制剂开发中怎么体现?Raw MaterialsWet GranulationFluid Bed DryingBlendingCompressionFill VolumeRotation SpeedEnd Point

    9、(Time)Blend UniformityDensitiesAngle of ReposeWhat is QbD?QbDQbD在制剂开发中怎么体现?在制剂开发中怎么体现?Raw MaterialsWet GranulationFluid Bed DryingBlendingCompressionFeed FrameToolingPunch Penetration DepthCompression ForcePress SpeedFeeder Speed Examples of QbD questions under QbR Control of Drug Substance What is

    10、the drug substance specification?Does it include all the critical drug substance attributes that affect the manufacturing and quality of the drug product?(2 pages)Drug Product What attributes should the drug product possess?(1.5 pages)How were the excipients and their grades selected?How was the fin

    11、al formulation optimized?Manufacturing Process How are the manufacturing steps(unit operations)related to the drug product quality?How were the critical process parameters identified,monitored,and/or controlled?Pharmaceutical Development Manufacture Container Closure SystemAspectsTraditionalQbDPharm

    12、aceuticaldevelopmentEmpirical;univariateexperimentsSystematic;multivariateexperimentsManufacturingprocessFixed;validation on 3 initialfull-scale batches;focus on reproducibilityAdjustable within design space;continuous verification;focus on control strategyProcess controlIn-process testing for go/no

    13、go;offline analysis w/slow responsePAT utilized for feedback&feed forward,real timeProductspecificationPrimary means of qualitycontrol;based on batch dataPart of the overall qualitycontrol strategy;based ondesired product performanceControlstrategyMainly by intermediate andend product testingRisk-ba

    14、sed;controls shiftedupstream;real-time releaseLifecyclemanagementReactive to problems&OOS;post-approvalContinuous improvementenabled within design spaceQbDQbD小结小结-SUMMARY-SUMMARY研发研发(高难高难)仿制药的一些体仿制药的一些体会会Dissolution Profile-体外溶出曲线体外溶出曲线生物等效生物等效(BE)结果结果AUC0-tAUC0-infCmaxFastRatio108.01%108.12%86.26%9

    15、0%Geometric C.I.103.49%to 112.73%103.64%to 112.79%75.28%to 98.84%FedRatio111.21%112.48%85.24%90%Geometric C.I.104.40%to 118.47%105.78%to 119.60%73.47%to 98.90%Summary of in vivo study results of Test Formulation vs.RLD原因调查原因调查PRODUCT P DATA(Log Transformed Data,Fast,n-12)PRODUCT P DATA(Log Transform

    16、ed Data,FED,n-11)PRODUCT P DATA(Log Transformed Data)案例研究案例研究-402040608010004812162024Amount dissolved(%)Time(Hrs)Dissolution Profile for xxxx ER Formulation,USP Apparatus II,Water,50 RPM RefT-1T-2API is Water Soluble.Prototype formulation was proposed based on in vitro dissolution(OGD method).PRODU

    17、CT DATA(Log Transformed Data)AUC0-tAUC0-infCmaxT-1Ratio111.21%112.48%140%90%Geometric C.I.104.40%to 118.47%105.78%to 119.60%133.7%to 147.0%T-2Ratio117.5%117.2%135.9%90%Geometric C.I.113.2%to 122.2%112.4%to 122.1%129.5%to 142.4%Further Investigation02040608010012004812162024Amount dissolved(%)Time(Hrs)Simulated Dissolution for xxxx ER Formulation,RefT-2

    展开阅读全文
    提示  163文库所有资源均是用户自行上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作他用。
    关于本文
    本文标题:开发报批美国FDA的仿制药与相关问题探讨课件.ppt
    链接地址:https://www.163wenku.com/p-5043566.html

    Copyright@ 2017-2037 Www.163WenKu.Com  网站版权所有  |  资源地图   
    IPC备案号:蜀ICP备2021032737号  | 川公网安备 51099002000191号


    侵权投诉QQ:3464097650  资料上传QQ:3464097650
       


    【声明】本站为“文档C2C交易模式”,即用户上传的文档直接卖给(下载)用户,本站只是网络空间服务平台,本站所有原创文档下载所得归上传人所有,如您发现上传作品侵犯了您的版权,请立刻联系我们并提供证据,我们将在3个工作日内予以改正。

    163文库